


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449B/PTO		<b>Complete if Known</b>	
	<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
	Use as many sheets as necessary)		Filing Date	11/17/2003
			First Named Inventor	Gerald McMAHON
			Group Art Unit	1641
Examiner Name		Unassigned		
Attorney Docket Number		034536-0684		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code <sup>2</sup> (if known)			class	subclass
RR	A1	4,087,535		HEUBACH	05-02-1978	424	272
RR	A2	4,284,786		KÄMMERER et al.	08-18-1981	548	248
RR	A3	4,351,841		KÄMMERER et al.	09-28-1982	424	272
RR	A4	4,965,276		BARTLETT et al.	10-23-1990	514	378
RR	A5	4,992,271		FERNANDES et al.	02-12-1991	424	85.2
RR	A6	5,217,999	A	LEVITZKI et al.	06-08-1993	514	613
RR	A7	5,268,382	A	BARTLETT et al.	12-07-1993	514	378
RR	A8	5,314,685	A	TYLE et al.	05-24-1994	424	401
RR	A9	5,371,099	A	BARTLETT et al.	12-06-1994	514	378
RR	A10	5,403,858	A	BASTARD et al.	04-04-1995	514	449
RR	A11	5,476,866	A	KUO et al.	12-19-1995	514	378
RR	A12	5,494,911	A	BARTLETT et al.	02-27-1996	514	256
RR	A13	5,514,711	A	KITANO et al.	05-07-1996	514	521
RR	A14	5,532,259	A	BARTLETT et al.	07-02-1996	514	378
RR	A15	5,547,971	A	WEITHMANN et al.	08-20-1996	514	378
RR	A16	5,573,775	A	ROBERTSON et al.	11-12-1996	424	427
RR	A17	5,610,173	A	SCHWARTZ et al.	03-11-1997	514	378
RR	A18	5,700,822	A	HIRTH et al.	12-23-1997	514	380

Examiner Signature	<i>R. Raymond</i>	Date Considered	10-26-04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/713,201
				Filing Date	11/17/2003
				First Named Inventor	Gerald McMAHON
				Group Art Unit	1641
				Examiner Name	Unassigned
				Attorney Docket Number	034536-0684
Sheet	2	of	18		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code <sup>2</sup> (if known)				
RR	A19	5,700,823	A	HIRTH et al.	12-23-1997	514	380
RR	A20	5,783,592	A	SCHWARTZ et al.	07-21-1998	514	378
RR	A21	5,843,947	A	ROBERT et al.	12-01-1998	514	252
RR	A22	Re. 36,256	E	SPADA et al.	07-20-1999	514	249
RR	A23	5,932,602	A	HIRTH et al.	08-03-1999	514	380
RR	A24	5,958,959	A	HIRTH et al.	09-28-1999	514	378
RR	A25	5,990,141	A	HIRTH et al.	11-23-1999	514	378
RR	A26	6,020,372	A	SCHWAB et al.	02-01-2000	514	521
RR	A27	6,022,884	A	MANTLO et al.	02-08-2000	514	352
RR	A28	6,184,237	B1	MANTLO et al.	02-06-2001	514	335
RR	A29	6,187,797	B1	PRUITT et al.	02-13-2001	514	340
RR	A30	6,316,479	B1	McMAHON et al.	11-13-2001	514	378
RR	A31	6,333,341	B1	MANTLO et al.	12-25-2001	514	336

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)				
RR	A32	AU	31010/93	A	ZENECA LIMITED	07-22-1993	—	
RR	A33	DE	25 24 929	A1	HOECHST AG	12-16-1976	—	
RR	A34	EP	0 359 184	B1	BRISTOL-MYERS SQUIBB COMPANY	03-21-1990	—	

Examiner Signature	<i>RR Raimund</i>	Date Considered	10-26-04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/713,201		
		Filing Date	11/17/2003		
		First Named Inventor	Gerald McMAHON		
		Group Art Unit	1641		
		Examiner Name	Unassigned		
Sheet	3	of	18	Attorney Docket Number	034536-0684

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RR	A35	EP	0 413 329	B1	ALCON LABORATORIES, INC.	02-05-1997	—	
RR	A36	EP	0 520 722	B1	ZENECA LIMITED	12-30-1992	—	
RR	A37	EP	0 522 937	A1	RHONE-POULENC RORER SA	01-13-1993	—	
RR	A38	EP	0 537 742	B1	MITSUBISHI CHEMICAL CORPORATION	08-21-1996	—	
RR	A39	EP	0 551 230	B1	ROUSSEL-UCLAF	07-19-1995	—	
RR	A40	EP	0 607 775	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998	—	
RR	A41	EP	0 607 776	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998	—	
RR	A42	EP	0 607 777	B1	HOECHST AKTIENGESELLSCHAFT	12-09-1998	—	
RR	A43	EP	0 645 145	B1	BRISTOL-MYERS SQUIBB COMPANY	03-12-1997	—	
RR	A44	EP	0 665 013	B1	AVENTIS PHARMA DEUTSCHLAND GmbH	10-24-2001	—	
RR	A45	EP	0 769 296	B1	AVENTIS PHARMA DEUTSCHLAND GmbH	07-04-2001	—	
RR	A46	EP	0 804 191	B1	SUGEN, INC. et al.	05-17-2000	—	
RR	A47	GB	2 240 104	A	FARMITALIA CARLO ERBA SRL	07-24-1991	—	
RR	A48	WO	87/04436	A1	LUNDBLAD	07-30-1987	—	
RR	A49	WO	91/17748	A1	HOECHST AKTIENGESELLSCHAFT	11-28-1991	—	

Examiner Signature	<i>R. Raymond</i>	Date Considered	10-26-04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
		Attorney Docket Number	034536-0884
Sheet	4	of	18

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RR	A50	WO	92/02444	A1	THE DOW CHEMICAL COMPANY	02-20-1992	—	
RR	A51	WO	92/18481	A1	RHONEPOULENC RORER INTERNATIONAL	10-29-1992	—	
RR	A52	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992	—	
RR	A53	WO	92/21641	A1	PFIZER INC.	12-10-1992	—	
RR	A54	WO	94/26260	A1	YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	11-24-1994	—	
RR	A55	WO	95/19189	A2	SUGEN, INC. et al.	07-20-1995	—	
RR	A56	WO	95/21613	A1	YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	08-17-1995	—	
RR	A57	WO	96/33179	A1	SUGEN, INC.	10-24-1996	—	
RR	A58	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999	—	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
RR	A59	AAS et al., "Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth," <u>British Journal of Neurosurgery</u> 8(2):187-192 (1994).			
RR	A60	ANDREWS et al. (American Veterinary Medicine Association Panel on Euthana), "1993 Report of the AVMA Panel on Euthanasia," <u>J. American Veterinary Medicine Association</u> 202(2):229-249 (1993).			

Examiner Signature		Date Considered	10-26-04
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		<b>Application Number</b>	10/713,201
		<b>Filing Date</b>	11/17/2003
		<b>First Named Inventor</b>	Gerald McMAHON
		<b>Group Art Unit</b>	1641
		<b>Examiner Name</b>	Unassigned
		<b>Attorney Docket Number</b>	034536-0684
Sheet	5	of	18

(use as many sheets as necessary)

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A61	BARTLETT et al., "Effects of leflunomide on immune responses and models of inflammation," <u>Springer Semin. Immunopathol.</u> 14:381-394 (1993).	
RR	A62	BARTLETT et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," <u>Agents and Actions</u> 32:10-21 (1991).	
RR	A63	BARTLETT et al., "Leflunomide: A novel immunomodulating drug in Nonsteroidal Anti-Inflammatory Drugs" 2nd ed. pp. 349-366, Lewis and Furstk eds., Dekker, NY, (1985).	
RR	A64	BARTLETT et al., <u>Chemical Abstracts</u> 116:128908, 1992	
RR	A65	BASERGA et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," <u>J. of Natl. Cancer Institute</u> 85(16):1327-1333 (1993).	
RR	A66	BAUDY et al., "Potent Quinoxaline-Spaced Phosphono alpha-Amino Acids of the AP-6 Type as Competitive NMDA Antagonists: Synthesis and Biological Evaluation," <u>J. Med. Chem.</u> 36:331-342 (1993).	
RR	A67	BILDER et al., "Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," <u>Am. J. Physiol.</u> 260(Cell Physiol.29):C721-C730 (1991).	
RR	A68	BIRCHALL et al., "Compositions for killing internal parasites containing 3-teri-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," <u>Chemical Abstracts</u> 88:535 (1978).	
RR	A69	BRYCKAERT et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," <u>Exp. Cell Research</u> 199:255-261 (1992).	
RR	A70	BUSTELO and BARBACID, "Tyrosine Phosphorylation of the vav Proto-Incogene Product in Activated B Cells," <u>Science</u> 256: 1196-1199 (1992).	
RR	A71	CARAGLIA et al., "Cytosine arabinoside increases the binding of 125 I-labelled epidermal growth factor and 125 I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor)mAb," <u>Cancer Immunol. Immunother.</u> 37:150-156 (1993).	
RR	A72	CARBONI et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," <u>J. Am. Chem. Soc.</u> 80:2838-2840 (1958).	
RR	A73	<u>Cecil Textbook of Medicine</u> , Eds: Wyngaarden, Smith, Bennett, W. B. Saunders p. 2220, (1992).	

Examiner Signature	<i>RR Paymel</i>	Date Considered	10-26-04
--------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/713,201 11/17/2003 Gerald McMAHON 1641 Unassigned 034536-0684
Sheet	6	of	18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>9</sup>
RR	A74	CHARETTE et al., "Contemporary approaches of chemotherapy," <u>Neuro-Oncology</u> , 7(1):135 (1995)	
RR	A75	CHEN and OKAYAMA, "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA," <u>BioTech</u> , 6:632-638 (1988).	
RR	A76	CHERWINSKI et al., "The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism," <u>J. Pharmacology and Exp. Therap.</u> 227:460-468 (1995).	
RR	A77	CHONG et al., "Leflunomide, A Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosuppression," <u>Transplant. Proc.</u> 25:747-749 (1993).	
RR	A78	CHONG et al., "Leflunomide, A Novel Immunosuppressive Agent," <u>Transplantation</u> 55:1361-1366 (1993).	
RR	A79	COGHLAN et al., <u>Chemical Abstracts</u> 123:285992, 1995	
RR	A80	CONN et al., "Purification of a glycoprotein vascular endothelial cell mitogen from a rat glimo-derived cell line," <u>Proc. Natl. Acad. Sci. USA</u> 87:1323-1327 (1990).	
RR	A81	DAINIPPON PHARM., <u>Chemical Abstracts</u> 72:12709, 1970	
RR	A82	DATI et al., "Inhibition of c-erb-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990).	
RR	A83	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 115:61-69 (1988).	
RR	A84	EHRlich and BOGERT, "Experiments in the Veratrole and Quinoxaline Groups," <u>J. Org. Chem.</u> 12:522 (1947).	

Examiner Signature	<i>R. R. Rasmussen</i>	Date Considered	10-26-04
--------------------	------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0684
Sheet	7	of	18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A85	FERRIS et al., "Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <u>J. Org. Chem.</u> 44(2):173-178 (1979).	
RR	A86	FINLAY, "The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors," <u>Bone Marrow Transplantation</u> 18(Suppl. 3):S1-S5 (1996).	
RR	A87	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43S:47-54 (1993).	
RR	A88	FRY et al., "New insights into protein-tyrosine kinase receptor signaling complexes," <u>Protein Science</u> 2:1785-1797 (1993).	
RR	A89	FUMIHIRO "Injection Containing Etoposide," Application no. JP60239415 published Nov. 28 1995.	
RR	A90	GAZIT et al., "Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Med. Chem.</u> 32:2344-2352 (1989).	
RR	A91	GAZIT et al., "Tyrphostins. 2. Heterocyclic and alpha-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991).	
RR	A92	GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a .alpha.-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins" <u>J. Med. Chem.</u> 36:3556-3564 (1993).	
RR	A93	GLANT et al., "Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide," <u>Immunopharmacology</u> 23:105-116 (1992).	

Examiner Signature	<i>RR Raymond</i>	Date Considered	10-26-04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0684
Sheet	8	of	18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A94	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):331-314 (1988).	
RR	A95	GULBINS et al., "Tyrosine Kinase-Stimulated Guanine Nucleotide Exchange Activity of Vav in T Cell Activation," <u>Science</u> 260:822-825 (1993).	
RR	A96	HALE et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," <u>J. Clin. Pathol.</u> 46:149-153 (1993).	
RR	A97	HAMBLETON and MAHON, "Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis" <u>Agents and Actions</u> 29:328-332 (1990).	
RR	A98	HARRIS et al., "Breast Cancer (First of Three Parts)," <u>New England J. of Medicine</u> 327(5):319-328 (1992).	
RR	A99	HELDIN, "Structural and functional studies on platelet-derived growth factor," <u>EMBO Journal</u> 11:4251-4259 (1992).	
RR	A100	HOCHBERG et al., "Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study," <u>Neuro-Oncology</u> 32(1):45-55 (1997)	
RR	A101	HOEKSTRA et al., "Differential effects of steurosporine and tyrphostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," <u>Experimental Therapeutics from 84th Annual Meeting of American Association for Cancer Research</u> , vol. 34, #2455 (1993).	
RR	A102	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987).	

Examiner Signature	<i>R. Raymond</i>	Date Considered	10-26-04
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden-Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0684
Sheet	9	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>o</sup>
RR	A103	HOUCK et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," <u>Molecular Endocrinology</u> 5:1806-1814 (1991).	
RR	A104	ISSIDORIDES and HADDADIN, "Benzofurazan Oxide. II. Reactions with Enolate Anions," <u>J. Org. Chem.</u> 31:4067-4068 (1966).	
RR	A105	JASCHKE et al., <u>Chemical Abstracts</u> 120:217654, 1994	
RR	A106	JU et al., "Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture," <u>Acta Pharmacological Sinica</u> 15:2232-26 (1994).	
RR	A107	JU et al., "Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages," <u>Acta Pharmacological Sinica</u> 92:90-94 (1994).	
RR	A108	KAEMMERER et al., <u>Chemical Abstracts</u> 89:109449, 1978	
RR	A109	KARAMERIS et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas, An Immunohistological Study of 63 Cases," <u>Path. Res. Pract.</u> 189:133-137 (1993).	
RR	A110	KAUR, "Tyrophostin induced growth inhibitions: correlation with effect on p210.bcr-abl autokinase activity in K562 chronic myelogenous leukemia," <u>Anti-Cancer Drugs</u> 5:213-222 (1994).	
RR	A111	KIU et al., "Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas," <u>Neuro-oncology</u> 25(3):215-220 (1995)	

Examiner Signature	<i>RR Rummel</i>	Date Considered	10-26-04
--------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

## Complete if Known

Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

(use as many sheets as necessary)

Sheet 10 of 18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A112	KOENDERS et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," <u>Breast Cancer Research and Treatment</u> 25:21-27 (1993).	
RR	A113	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313 (1983).	
RR	A114	KOVALENKO et al., "Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation," <u>Cancer Research</u> 54:6106-6114 (1994).	
RR	A115	KUECHLE et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent," <u>Transplant Proc.</u> 23:1083-1806 (1991).	
RR	A116	KURPAD et al., Intraarterial O <sup>6</sup> -benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea," <u>Cancer Chemotherapy and Pharmacology</u> 39(4):307-316 (1997).	
RR	A117	LEE and SALEMNICK, "Purine N-Oxides, LXII. 2,4-Dioxophyrido-2,3-d-pyrimidine N-Oxides," <u>J. Org. Chem.</u> 40(24):3608-3610 (1975).	
RR	A118	LEVITZKI, "Tyrophostins -- Potential Antiproliferative Agents and Novel Molecular Tools," <u>Biochem. Pharm.</u> 40(5):913-918 (1990).	
RR	A119	LEY and SENG, "Synthesis unter Verwendung von Benzofuroxan," <u>Syntheses</u> 1975:415-422 (1975).	
RR	A120	LOS MARIO, <u>Chemical Abstracts</u> 102:45926, 1985	

Examiner Signature

Date Considered

10-26-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

\*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0584
Sheet	11	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A121	LYALL et al., "Tyrophostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <u>J. Bio. Chem.</u> , 264:14503-14509 (1989).	
RR	A122	MALKIN et al., "Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma," <u>Proc Annu. Meet Am. Soc. Clin. Oncol.</u> 16:A1371 (1997)	
RR	A123	MANDAL et al., <u>Chemical Abstracts</u> 106:138320, 1987	
RR	A124	MANTLO et al., <u>Chemical Abstracts</u> 130:352186, 1999	
RR	A125	MARSHALL, E., "Search for a Killer: Focus Shifts from Fat to Hormones," <u>Science</u> 259:618-621 (1993).	
RR	A126	MATTAR et al., "Effect of leflunomide active metabolite, A771726, on signal transduction pathways necessary for proliferation," <u>Immunobiology</u> 186(1-2):43 (1992) (abstract).	
RR	A127	MATTAR et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," <u>FEBS Letters</u> 334 (2):161-164 (1993).	
RR	A128	MCCHESENEY et al., "An Evaluation of Leflunomide in the Canine Real Transplantation Model," <u>Transplantation</u> 57:1717-1722 (1994).	
RR	A129	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993).	
RR	A130	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983).	

Examiner Signature	<i>R. P. [Signature]</i>	Date Considered	10-26-04
--------------------	--------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
Sheet	12	of	18
		Attorney Docket Number	034536-0684

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RR	A131	MULLER et al., "BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia Chromosome-Positive Human Leukemias," <u>Mol. Cell. Biol.</u> 11:1785-1792 (1991).	
RR	A132	MYERS et al., See Abs. Attached, <u>Curr. Pharm. Design</u> , 3/5, 1997	
RR	A133	NICHTERLEIN et al., "Leflunomide (HWA 486) Prolongs Course of Murine Listeriosis," <u>Immunol. Infect. Dis.</u> 4:18-22 (1994).	
RR	A134	OGAWA et al., "Effects of leflunomide on glomerulonephritis induced by ant basement membrane antibody in rats," <u>Agents Actions</u> 31:321-328 (1990).	
RR	A135	OGAWA et al., "Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Ant basement Membrane Antibody in Rats," <u>Clin. Immunol. Immunopath.</u> 61:103-118 (1991).	
RR	A136	OHMACHI et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor," <u>Biochemistry</u> 32:4650-4658 (1993).	
RR	A137	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985).	
RR	A138	OSHEROV et al., "Selective Inhibition of the EGF and Neu receptors by Tyrophostins," <u>J. Cell Biochem.</u> S17A:237 (1993).	
RR	A139	OSHEROV et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tyrophostins," <u>J. Bio. Chem.</u> 268:11134-11142 (1993).	

Examiner Signature	<i>R. R. Parnell</i>	Date Considered	10-26-01
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0684
Sheet	13	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RR	A140	OZZELO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cells Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980).	
RR	A141	PALOMO COLL, <u>Chemical Abstracts</u> 85:62229, 1976	
RR	A142	PARK et al., <u>Chemical Abstracts</u> 114:81672, 1991	
RR	A143	PATTERSON et al., "3-Carboxy-5-methyl-N-4-(trifluoromethyl)phenyl-4-isoxazolecarboxamide, a New Prodrug for the Antiarthritic Agent 2-Cyano-3-hydroxy-N-4-(trifluoromethyl)phenyl-2-butenamide," <u>J. Med. Chem.</u> 35:507-520 (1992).	
RR	A144	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <u>The Prostate</u> 22:335-345 (1993).	
RR	A145	PIGOTT et al., "Expression of epidermal growth factor receptor in human glioblastoma multiforme," <u>Brit. J. of Neurosurgery</u> 7:261-265 (1993).	
RR	A146	PLATE et al., "Platelet-Derived Growth Factor Receptor-beta is Induced during Tumor Development and Upregulated during Tumor Progression in Endothelial Cells in Human Gliomas," <u>Laboratory Investigation</u> 4:529-534 (1992).	
RR	A147	PLATE et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," <u>Cancer Research</u> 53:5822-5827 (1993).	
RD	A148	PLATE et al., "Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo," <u>Nature</u> 359:845-848 (1992).	

Examiner Signature	<i>R. R. Ruppel</i>	Date Considered	10-26-04
--------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/713,201 11/17/2003 Gerald McMAHON 1641 Unassigned 034536-0684
Sheet	14	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A149	PLOWMAN et al., "Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-Bis(2-chloroethyl)-1-nitrosourea" <u>Cancer Research</u> 54(14):3793-3799 (1994)	
RR	A150	POLLACK et al., "Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium," <u>J. Neurosurg.</u> 73:106-112 (1990).	
RR	A151	PRUITT et al., <u>Chemical Abstracts</u> 134:163023, 2001	
RR	A152	REN et al., "Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site," <u>Science</u> 259:1157-1161 (1993).	
RR	A153	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <u>Biochem. Pharm.</u> 44(5):881-888 (1992).	
RR	A154	ROBERT et al., <u>Chemical Abstracts</u> 124:202306, 1996	
RR	A155	ROSEN et al., "A phase I/II study of SU101 in patients with ovarian, prostate, and non-small cell lung cancers," <u>Proc. Annu. Meet. Am. Soc. Clin. Oncol.</u> 16:A739 (1997).	
RR	A156	ROSENTHAL et al., "Conditioned Medium from Mouse Sarcoma 180 Cells Contains Vascular Endothelial Growth Factor," <u>Growth Factors</u> 4:53-59 (1990).	
RR	A157	ROSS, "The pathogenesis of atherosclerosis: a perspective for the 1990s," <u>Nature</u> 362:801-809 (1993).	

Examiner Signature	<i>RR Raymond</i>	Date Considered	10-26-00
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
		Attorney Docket Number	034536-0684
Sheet	15	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A158	RUSCH et al., "Differential Expression of the Epidermal Growth Factor Receptor and Its Ligands in Primary Non-Small Cell Lung Cancers and Adjacent Benign Lung," <u>Cancer Research</u> 53:2379-2385 (1993).	
RR	A159	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to Nude Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969).	
RR	A160	RYING et al., <u>Chemical Abstracts</u> 127:121701, 1997	
RR	A161	SCHORLEMMER et al., "Prolongation of Allogeneic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, A New Immunosuppressive Isoxazol Derivative," <u>Transplant. Proc.</u> 25:763-767 (1993).	
RR	A162	SCHORNAGEL et al., "Synthesis and Evaluation of 2,4-Diaminoquinazoline Antioflates with Activity Against Methotrexate-Resistant Human Tumor Cells," <u>Biochem. Pharm.</u> 33(20):3251-3255 (1984).	
RR	A163	SCHWAB et al., <u>Chemical Abstracts</u> 126:325499, 1997	
RR	A164	SCOTT et al., "p185.HER2 Signal Transduction in Breast Cancer Cells," <u>J. Bio. Chem.</u> 266(22):14300-14305 (1991).	
RR	A165	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983).	
RR	A166	SHAFIE and GRANTHAM, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67(1):51-56 (1981).	

Examiner Signature	<i>R. R. Raimund</i>	Date Considered	10-26-04
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/713,201
		Filing Date	11/17/2003
		First Named Inventor	Gerald McMAHON
		Group Art Unit	1641
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-0684
Sheet	16	of	18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
RR	A167	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992).	
RR	A168	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990).	
RR	A169	TALMADGE and TWARDZIK, "Role of Cytokines in Inflammation and Autoimmunity," <u>Agents and Actions</u> 35S:135-141 (1991).	
RR	A170	THOENES et al., "Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointerstitial Nephritis in Rats," <u>Int. J. Immunopharmacol.</u> 11:921-929 (1989).	
RR	A171	UENO et al., "Inhibition of PDGF beta Receptor Signal Transduction by Coexpression of a Truncated Receptor," <u>Science</u> 252:844-852 (1991).	
RR	A172	ULRICHS et al., "Suppression of Natural Xenophile Antibodies With the Novel Immunomodulating Drug Leflunomide," <u>Transplant Proc.</u> 24:718-719 (1992).	
RR	A173	VAN der WALL et al., "High-dose chemotherapy regimens for solid tumors," <u>Cancer Treatment Reviews</u> 21(2):105-132 (1995)	
RR	A174	Van UMMERSEN et al., "A phase I trial of SU101 in patients with solid tumors," <u>Proc. Annu. Meet. Am. Soc. Clin. Oncol.</u> 16:A740 (1997)	
RR	A175	WADA et al., "Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins," <u>Oncogene</u> 5:489-495 (1990).	

Examiner Signature	<i>R. R. Rammell</i>	Date Considered	10-26-04
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/713,201
Filing Date	11/17/2003
First Named Inventor	Gerald McMAHON
Group Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	034536-0684

Sheet 17 of 18

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RR	A176	WALTENBERGER et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 269:26988-26995 (1994).	
RR	A177	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991).	
RR	A178	WEDGE et al., "O <sup>6</sup> -benzylguanine enhances the sensitivity of a glioma xenograft with low O <sup>6</sup> -alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU," <u>British Journal of Cancer</u> 73(9):1049-1052 (1996).	
RR	A179	WEITHMANN et al., "Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation," <u>Agents Actions</u> 41:164-170 (1994).	
RR	A180	WHITE, <u>Chemical Abstracts</u> 111:227133, 1989	
RR	A181	WILLIAMS et al., "Immunosuppressive Effects of Leflunomide in a Cardiac Allograft Model," <u>Transplantation Proc.</u> 25:745-746 (1993).	
RR	A182	WILLIAMS et al., "Leflunomide in Experimental Transplantation," <u>Transplantation</u> 57:1223-1231 (1994).	
RR	A183	XIAO et al., "Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts," <u>Transplantation Proceedings</u> 26:1263-1265 (1994).	
RR	A184	XIAO et al., "Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts," <u>Transplantation</u> 58:828-834 (1994).	
RR	A185	YAISH et al., "Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors," <u>Science</u> 242:933-935 (1988).	
RR	A186	YONEDA et al., "The Antioproliferative Effects of Tyrosine Kinase Inhibitors Tyrphosins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice," <u>Cancer Research</u> 51:4430-4435 (1991).	

Examiner  
SignatureDate  
Considered

10-26-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

**Substitute for form 1449B/PTO**  
**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

**Complete if Known**

<b>Application Number</b>	10/713,201
<b>Filing Date</b>	11/17/2003
<b>First Named Inventor</b>	Gerald McMAHON
<b>Group Art Unit</b>	1641
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	034536-0684

Sheet	18	of	18
-------	----	----	----

## NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

10-26-a

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.